Compare MCD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | JNJ |
|---|---|---|
| Founded | 1940 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6B | 542.4B |
| IPO Year | 1996 | 2003 |
| Metric | MCD | JNJ |
|---|---|---|
| Price | $268.27 | $253.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 20 |
| Target Price | ★ $344.17 | $238.20 |
| AVG Volume (30 Days) | 4.2M | ★ 7.7M |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.56% | 2.36% |
| EPS Growth | 4.92 | ★ 90.50 |
| EPS | ★ 2.78 | 2.14 |
| Revenue | ★ $26,885,000,000.00 | N/A |
| Revenue This Year | $7.65 | $6.63 |
| Revenue Next Year | $6.00 | $7.43 |
| P/E Ratio | ★ $95.24 | $114.54 |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $264.60 | $151.52 |
| 52 Week High | $341.75 | $251.71 |
| Indicator | MCD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 71.37 |
| Support Level | N/A | $233.83 |
| Resistance Level | $311.08 | N/A |
| Average True Range (ATR) | 5.46 | 5.06 |
| MACD | -1.21 | 1.69 |
| Stochastic Oscillator | 15.06 | 97.58 |
McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.